Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 68, Issue 2, 1999, Pages 473-478

  Khan, Mohammad M H ^b   Gikakis, Nicolas ^b   Miyamoto, Shinji ^b   Rao, A Koneti ^b   Cooper, Stuart L ^b   Edmunds Jr , L Henry ^b   Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CD11B ANTIGEN; HEPARIN; KALLIKREIN; PROCOAGULANT; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; HEPARINIZATION; HUMAN; HUMAN CELL; MONOCYTE; OPEN HEART SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMULATION;

ANTITHROMBIN III; APROTININ; CARDIOPULMONARY BYPASS; FACTOR VIIA; HEMOSTATICS; HUMANS; MACROPHAGE-1 ANTIGEN; MODELS, CARDIOVASCULAR; MONOCYTES; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; THROMBOPLASTIN;

EID: 0032759638     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00551-2     Document Type: Conference Paper

References (25)

1. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
2. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
3. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
4. Lemmer JH, Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-68.
5. Tatar H, Cicek S, Demirkilic U, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993;55:659-61.
6. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-83.
7. Chabbat J, Porte P, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993;71:205-15.
8. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-10.
9. Tabuchi N, Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:828-33.
10. Gram J, Janetzko T, Jespersen J, Bruhn HD. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemost 1990;63:241-5.
11. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-96.
12. Lu H, Soria C, Commin PL, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991;66:633-7.
13. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-44.
14. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72: 1075-81.
15. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH, Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996;93:2014-8.
16. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72:1841-8.
17. Nemerson Y. Analysis of the kinetics of factor X activation by tissue factor-factor VIIA. Haemostasis 1996;26(Suppl 4):98-101.
18. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-4.
19. Wachtfogel YT, Kucich U, James HL, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-7.
20. Wendel HP, Heller W, Gallimore MJ. Aprotinin in therapeutic doses inhibits chromogenic assay for protein C. Thromb Res 1994;74:543-8.
21. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986;68:1218-23.
22. Wachtfogel YT, Harpel PC, Edmunds LH, Jr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989;73:468-71.
23. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb/IIIa after plasmin stimulation. Blood 1991;77:694-9.
24. Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996;62:410-8.
25. Tabuchi N, de Hoan J, van Oeveren W. Topical effect of aprotinin on the surgical wound in cardiac surgery [Letter] J Thorac Cardiovasc Surg 1995;109:399-400.